These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
438 related articles for article (PubMed ID: 34720089)
1. CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses. Ma B; Akosman B; Kamle S; Lee CM; He CH; Koo JS; Lee CG; Elias JA J Clin Invest; 2021 Nov; 131(21):. PubMed ID: 34720089 [TBL] [Abstract][Full Text] [Related]
2. CHI3L1 enhances melanoma lung metastasis Ma B; Kamle S; Akosman B; Khan H; Lee CM; Lee CG; Elias JA Front Immunol; 2022; 13():1056397. PubMed ID: 36618349 [TBL] [Abstract][Full Text] [Related]
3. RIG-like Helicase Regulation of Chitinase 3-like 1 Axis and Pulmonary Metastasis. Ma B; Herzog EL; Moore M; Lee CM; Na SH; Lee CG; Elias JA Sci Rep; 2016 May; 6():26299. PubMed ID: 27198666 [TBL] [Abstract][Full Text] [Related]
4. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity. Kotanides H; Li Y; Malabunga M; Carpenito C; Eastman SW; Shen Y; Wang G; Inigo I; Surguladze D; Pennello AL; Persaud K; Hindi S; Topper M; Chen X; Zhang Y; Bulaon DK; Bailey T; Lao Y; Han B; Torgerson S; Chin D; Sonyi A; Haidar JN; Novosiadly RD; Moxham CM; Plowman GD; Ludwig DL; Kalos M Cancer Immunol Res; 2020 Oct; 8(10):1300-1310. PubMed ID: 32873605 [TBL] [Abstract][Full Text] [Related]
5. Regulation of chitinase-3-like-1 in T cell elicits Th1 and cytotoxic responses to inhibit lung metastasis. Kim DH; Park HJ; Lim S; Koo JH; Lee HG; Choi JO; Oh JH; Ha SJ; Kang MJ; Lee CM; Lee CG; Elias JA; Choi JM Nat Commun; 2018 Feb; 9(1):503. PubMed ID: 29403003 [TBL] [Abstract][Full Text] [Related]
6. Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy. Li T; Wang X; Niu M; Wang M; Zhou J; Wu K; Yi M Front Immunol; 2023; 14():1196970. PubMed ID: 37520520 [TBL] [Abstract][Full Text] [Related]
7. Tumor-Targeted Chemoimmunotherapy with Immune-Checkpoint Blockade for Enhanced Anti-Melanoma Efficacy. Li M; Yang Y; Xu C; Wei J; Liu Y; Cun X; Yu Q; Tang X; Yin S; Zhang Z; He Q AAPS J; 2019 Jan; 21(2):18. PubMed ID: 30635795 [TBL] [Abstract][Full Text] [Related]
8. Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle. Li C; Han X Pharm Res; 2020 May; 37(6):109. PubMed ID: 32476052 [TBL] [Abstract][Full Text] [Related]
9. The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 × αPD-L1 bispecific antibody-armed T cells. Cho J; Tae N; Song Y; Kim CW; Lee SJ; Ahn JH; Lee KH; Lee BH; Kim BS; Chang SY; Kim DH; Ko HJ Cancer Immunol Immunother; 2024 Aug; 73(10):196. PubMed ID: 39105814 [TBL] [Abstract][Full Text] [Related]
10. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547 [TBL] [Abstract][Full Text] [Related]
12. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
13. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis. Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026 [TBL] [Abstract][Full Text] [Related]
15. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA. Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915 [TBL] [Abstract][Full Text] [Related]
16. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity. Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020 [TBL] [Abstract][Full Text] [Related]
17. A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity. Huang PL; Kan HT; Hsu CH; Hsieh HT; Cheng WC; Huang RY; You JJ J Transl Med; 2023 May; 21(1):346. PubMed ID: 37226226 [TBL] [Abstract][Full Text] [Related]
19. A Three-in-One Immunotherapy Nanoweapon via Cascade-Amplifying Cancer-Immunity Cycle against Tumor Metastasis, Relapse, and Postsurgical Regrowth. Li Q; Zhang D; Zhang J; Jiang Y; Song A; Li Z; Luan Y Nano Lett; 2019 Sep; 19(9):6647-6657. PubMed ID: 31409072 [TBL] [Abstract][Full Text] [Related]
20. Knockdown of Chitinase 3-Like-1 Inhibits Cell Proliferation, Promotes Apoptosis, and Enhances Effect of Anti-Programmed Death Ligand 1 (PD-L1) in Diffuse Large B Cell Lymphoma Cells. Yang X; Fang D; Li M; Chen J; Cheng Y; Luo J Med Sci Monit; 2021 Mar; 27():e929431. PubMed ID: 33764958 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]